Additional effects of pioglitazone on type 2 diabetes who were inappropriately controled with

Additional effects of pioglitazone on type 2 diabetes who were inappropriately controled with - ACTION-J

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002333

Enrollment

100

Registered

2009-08-15

Start date

2007-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

The patients were randomly divided into 2 groups (oral pioglitazone titrated from 15 mg to 30 mg or no pioglitazone, to be taken in addition to their glucose-lowering drugs and other medications) matc

s decision during the study. any drugs other than pioglitazone are allowed to be used.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type 2 diabetes patients insulin therpy under inappropriate glycemic control. 1.the patients who get imformed consent with written paper. 2. the patients whose HbA1c has been more than 7.0% for more than 1 year

Exclusion criteria

Exclusion criteria: 1.the patients who had CVD or appoplexy within 6 months 2. the patients who have had hear failure (NYHA >III) 3. severe hepatic or renal failure 4. the patients who have had diabetic ketoacidosis 5. pregnant women 6. the pateints who has history of severe adverse effects with pioglitazone

Design outcomes

Primary

Measure	Time frame
1.HbA1C as glycemic control 2.Total daily dose and number of insulin 3.change of IMT	—

Secondary

Measure	Time frame
frequency of hypoglycemic attack	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026